Immune System May Play Role in Ocular Rosacea

Posted: 08/08/2013

New research into the development of subtype 4 ocular rosacea has found a strong correlation between certain components of the innate immune system and abnormalities in the blood vessels of the eyelids and eyes of those who suffer from the disorder.

The study was led by Dr. Edward Wladis, who was the recipient of a 2011 research grant from the NRS. The researchers investigated toll-like receptor-4 (TLR4) as well as a variety of vascular markers in eyelid biopsies from patients with ocular rosacea and individuals without the condition.

They found that levels of TLR4, proteins which play a key role in activating the innate immune system, were much higher in people with ocular rosacea. In addition, there were higher amounts of endoglin and a molecule that helps cells adhere to each other in the small blood vessels of ocular rosacea patients compared to those with normal skin. These molecules may cause inflammation in the blood vessels, leading to the bloodshot appearance common with ocular rosacea.

The researchers concluded that these molecules may represent targets to focus on therapies to help manage ocular rosacea.

Social Media Editor: Emma Terhaar

Follow us on Social Media





Contact Us

National Rosacea Society
196 James St.
Barrington, IL 60010

Our Mission

The National Rosacea Society is a 501(c)(3) nonprofit organization whose mission is to improve the lives of people with rosacea by raising awareness, providing public health information and supporting medical research on this widespread but little-known disorder. The information the Society provides should not be considered medical advice, nor is it intended to replace

consultation with a qualified physician. The Society does not evaluate, endorse or recommend any particular medications, products, equipment or treatments. Rosacea may vary substantially from one patient to another, and treatment must be tailored by a physician for each individual case. For more information, visit About Us.